 Merck Co. announced an agreement Thursday to buy Pandion Therapeutics Inc. in a deal valued at 1.85 billion. Under terms of the deal, Merck will pay 60 in cash for each Pandion share outstanding, which represents a 134.1 premium to Wednesdays closing price. 